The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: Study protocol for a multicenter randomized controlled study

Trials

Volumn 15, Issue 1, 2014, Pages

  Hosoya, Tatsuo ^a   Kimura, Kenjiro ^b   Itoh, Sadayoshi ^c   Inaba, Masaaki ^d   Uchida, Shunya ^e   Tomino, Yasuhiko ^f   Makino, Hirofumi ^g   Matsuo, Seiichi ^h   Yamamoto, Tetsuya ⁱ   Ohno, Iwao ^a   Shibagaki, Yugo ^b   Iimuro, Satoshi ^j   Imai, Naohiko ^b   Kuwabara, Masanari ^k   Hayakawa, Hiroshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

^j UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^k TORANOMON HOSPITAL   (Japan)

more..

Author keywords

Chronic kidney disease; Hyperuricemia; Placebo; Randomized controlled study; Reduced renal function; Urate lowering therapy; Xanthine oxidase inhibitor

Indexed keywords

GLUTAMINE;

ARTICLE; CRITICALLY ILL PATIENT; DIET SUPPLEMENTATION; DRUG MEGADOSE; ENTERIC FEEDING; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; GLOMERULAR FILTRATION RATE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; JAPAN; KIDNEY; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TABLETS; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; URIC ACID;

EID: 84892395808     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-26     Document Type: Article

References (48)

1. Mikkelsen WM, Dodge HJ, Valkenburg H. The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan 1959-1960. Am J Med 1965, 39:242-251. 10.1016/0002-9343(65)90048-3, 14320691.
2. Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism Japanese for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011, 30:1018-1029. 10.1080/15257770.2011.596496, 22132951, Japanese Society of Gout and Nucleic Acid Metabolism.
3. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004, 44:642-650.
4. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008, 19:1204-1211. 10.1681/ASN.2007101075, 2396939, 18337481.
5. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50:239-247. 10.1053/j.ajkd.2007.05.013, 17660025.
6. Neogi T. Clinical practice: gout. N Engl J Med 2011, 364:443-452. 10.1056/NEJMcp1001124, 21288096.
7. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010, 6:30-38. 10.1038/nrrheum.2009.236, 20046204.
8. Uchida S, Inokami T, Yamashita M. Implication of hyperuricemia and its treatment in progressive renal diseases. Nephrol Fronti 2006, 5:135-136.
9. Japan Nephrology Society Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012 [Article in Japanese]. Nihon Jinzo Gakkai Shi 2012, 54:1031-1189. Japan Nephrology Society.
10. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51-59. 10.1053/j.ajkd.2005.10.006, 16377385.
11. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5:1388-1393. 10.2215/CJN.01580210, 2924417, 20538833.
12. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005, 76:1835-1847. 10.1016/j.lfs.2004.10.031, 15698861.
13. Hoshide S, Nishimura S, Ishii S, Matsuzawa K, Saito N, Tanaka T. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in humans. Drug Metab Rev 2000, 32:269.
14. Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharcol 2011, 51:189-201.
15. Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther Adv Musculoskelet Dis 2011, 3:245-253. 10.1177/1759720X11416405, 3383531, 22870483.
16. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52:916-923. 10.1002/art.20935, 15751090.
17. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 2011, 17:7-13. 10.1097/RHU.0b013e318204aab4, 21169856.
18. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2009, 48:188-194.
19. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol 2011, 17:S50-S56. 10.1097/RHU.0b013e31822541d0, 21654270.
20. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663. 10.1001/archinte.164.6.659, 15037495.
21. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984, 108:1347-1352. 10.1016/0002-8703(84)90763-4, 6496291.
22. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990, 300:297-300. 10.1136/bmj.300.6720.297, 1661920, 2106959.
23. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005, 68:228-236. 10.1111/j.1523-1755.2005.00397.x, 15954912.
24. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007, 18:1307-1315. 10.1681/ASN.2006101159, 17344421.
25. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305. 10.1056/NEJMoa041031, 15385656.
26. Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int 1997, 51:850-854. 10.1038/ki.1997.119, 9067920.
27. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the Japanese general population: A longitudinal 10-year follow-up study. Hypertens Res 2008, 31:433-441. 10.1291/hypres.31.433, 18497462.
28. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006, 69:375-382. 10.1038/sj.ki.5000058, 16408129.
29. Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011, 26:379-385. 10.1007/s11606-010-1511-x, 3055978, 20853156.
30. Nogueira J, Weir M. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. Clin J Am Soc Nephrol 2007, 2:766-785. 10.2215/CJN.04131206, 17699494.
31. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006, 69:1264-1271. 10.1038/sj.ki.5000284, 16501489.
32. Spector T, Johns DG. Stoichiometric inhibition of reduced xanthine oxidase by hydroxypyrazolo [3,4-d]pyrimidines. J Biol Chem 1970, 245:5079-5085.
33. Massey V, Komai H, Palmer G, Elion GB. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem 1970, 245:2837-2844.
34. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003, 278:1848-1855. 10.1074/jbc.M208307200, 12421831.
35. Yamamoto T, Moriwaki Y, Fujimura Y, Takahashi S, Tsutsumi Z, Tsutsui T, Higashino K, Hada T. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 2000, 60:34-40. 10.1159/000028344, 10629441.
36. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106. 10.1161/hy1101.092839, 11711505.
37. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002, 13:2888-2897. 10.1097/01.ASN.0000034910.58454.FD, 12444207.
38. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:F991-F997.
39. Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008, 23:1179-1185.
40. Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, Zhao L, Johnson RJ. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008, 108:69-78.
41. Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004, 23:1117-1118. 10.1081/NCN-200027377, 15571212.
42. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005, 12:22-34. 10.1097/00045391-200501000-00005, 15662289.
43. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61-65. 10.1097/01.rhu.0000209882.50228.9f, 16601538.
44. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007, 20:391-395. 10.1111/j.1525-139X.2007.00270.x, 17897242.
45. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461. 10.1056/NEJMoa050373, 16339094.
46. Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540-1548. 10.1002/art.24209, 18975369.
47. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol 2011, 17:S13-S18. 10.1097/RHU.0b013e31821d36cc, 21654265.
48. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12:R63. 10.1186/ar2978, 2888216, 20370912.